DoH Policies screened during the period: 1st July 2019-30th September 2019
Topics:
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact assessment (EQIA).
Documents
- NICE Technology Appraisal TA567 - Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
- NICE Technology Appraisal TA573 - Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
- NICE Technology Appraisal TA569 - Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
- NICE Technology Appraisal TA574 - Certolizumab pegol for treating moderate to severe plaque psoriasis
- NICE Technology Appraisal TA559 - Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies
- Protect Life 2 - A Strategy for Preventing Suicide and Self Harm in Northern Ireland 2019-2024
- The Pharmaceutical Services (Amendments Relating to Serious Shortage Protocols) Regulations (NI) 2019